BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rossi RE, Garcia-Hernandez J, Meyer T, Thirlwell C, Watkins J, Martin NG, Caplin ME, Toumpanakis C. Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Ann Transl Med. 2015;3:118. [PMID: 26207246 DOI: 10.3978/j.issn.2305-5839.2015.04.23] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
Number Citing Articles
1 Gradiz R, Silva HC, Carvalho L, Botelho MF, Mota-Pinto A. MIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors. Sci Rep 2016;6:21648. [PMID: 26884312 DOI: 10.1038/srep21648] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
2 Pifano M, Garona J, Capobianco CS, Gonzalez N, Alonso DF, Ripoll GV. Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells. Front Oncol 2017;7:11. [PMID: 28194370 DOI: 10.3389/fonc.2017.00011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
3 Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Watanabe K, Nakamura J, Kikuchi H, Waragai Y, Takasumi M, Kawana S, Hashimoto Y, Hikichi T, Ohira H. Pancreatic neuroendocrine tumor Grade 1 patients followed up without surgery: Case series. World J Clin Oncol 2017; 8(3): 293-299 [PMID: 28638801 DOI: 10.5306/wjco.v8.i3.293] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Chen X, Guo C, Cui W, Sun K, Wang Z, Chen X. CD56 Expression Is Associated with Biological Behavior of Pancreatic Neuroendocrine Neoplasms. Cancer Manag Res 2020;12:4625-31. [PMID: 32606955 DOI: 10.2147/CMAR.S250071] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Papalou O, Peppa M, Kandaraki E, Diamanti-kandarakis E, Nikou G. The Diagnostic Value of Chromogranin A in Neuroendocrine Neoplasms is Potentiated by Clinical Factors and Inflammatory Markers. Endocrines 2020;1:1-12. [DOI: 10.3390/endocrines1010001] [Reference Citation Analysis]
6 Riechelmann RP, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute AR, Dos Santos A, Hoff AA, Gumz B, Buchpiguel C, Vilhena Pereira BS, Lourenço Junior DM, da Rocha Filho DR, Fonseca EA, Riello Mello EL, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, de Paulo GA, Girotto GC, Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JF, de Meirelles LR, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MC, Pereira MA, Barros M, Forones NM, do Amaral PC, de Medeiros RS, Araujo RL, Bezerra RO, Peixoto RD, Aguiar S Jr, Ribeiro U Jr, Pfiffer T, Hoff PM, Coutinho AK. Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience 2017;11:716. [PMID: 28194228 DOI: 10.3332/ecancer.2017.716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]